{
    "id": 29632,
    "fullName": "RNPC3 - ROS1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RNPC3-ROS1 results from the fusion of RNPC3 and ROS1 (PMID: 27370605). RNPC3-ROS1 has been identified in non-small cell lung cancer (PMID: 27370605), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 55599,
        "geneSymbol": "RNPC3",
        "terms": [
            "RNPC3",
            "IGHD5",
            "RBM40",
            "RNP",
            "SNRNP65"
        ]
    },
    "variant": "RNPC3 - ROS1",
    "createDate": "03/29/2019",
    "updateDate": "10/15/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 6098,
                "geneSymbol": "ROS1",
                "terms": [
                    "ROS1",
                    "c-ros-1",
                    "MCF3",
                    "ROS"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 9718,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer harboring EZR-ROS1 and RNPC3-ROS1 fusions that acquired resistance to Xalkori (crizotinib) demonstrated partial response to treatment with Cometriq (cabozantinib) prior to progressing after approximately 10 weeks (PMID: 27370605).",
            "molecularProfile": {
                "id": 31717,
                "profileName": "EZR - ROS1 RNPC3 - ROS1"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16632,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ROS1-rearranged non-small cell lung cancer acquired resistance to Xalkori (crizotinib) after initial response, sequencing of the pleural effusion identified EZR-ROS1 and RNPC3-ROS1 at the time of progression (PMID: 27370605).",
            "molecularProfile": {
                "id": 31717,
                "profileName": "EZR - ROS1 RNPC3 - ROS1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31716,
            "profileName": "RNPC3 - ROS1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31717,
            "profileName": "EZR - ROS1 RNPC3 - ROS1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}